Data from the Kingdom of Saudi Arabia (KSA) suggest that some patients with relapsing-remitting multiple sclerosis (RRMS) may not be optimally treated because some physicians delay the use of highly effective disease-modifying treatments.

A virtual meeting of expert Saudi neurologists identified a number of unmet needs for patients with RRMS in the KSA, including treatment choices that must compromise efficacy for safety or vice versa and inconvenient or complex dosage regimens.

B cells play an important role in MS pathogenesis, and treatments that target B cells, including ofatumumab, improve clinical outcomes in RRMS patients.

In clinical trials, ofatumumab significantly reduced relapse rates, confirmed disability worsening, and active lesions on magnetic resonance imaging compared with teriflunomide, with no increase in the incidence of adverse events, including serious infections.